Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Marta Alonso‐Peña, María Del Barrio, Ana Peleteiro‐Vigil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10718-10718
Open Access | Times Cited: 10

Showing 10 citing articles:

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 26
Diet-Induced Gut Dysbiosis and Leaky Gut Syndrome
Yu-Rim Chae, Yu Ra Lee, Young‐Soo Kim, et al.
Journal of Microbiology and Biotechnology (2024) Vol. 34, Iss. 4, pp. 747-756
Open Access | Times Cited: 21
Redox regulation: mechanisms, biology and therapeutic targets in diseases
Bowen Li, Hui Ming, Siyuan Qin, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Exploring Systemic Impacts and Innovative Therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102584-102584
Closed Access
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
(2024)
Open Access | Times Cited: 1
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Analysis of gene expression changes during lipid droplet formation in HepG2 human liver cancer cells
Mitsuru Chiba, Y Ohsugi, Kana Matsumoto, et al.
Medicine International (2024) Vol. 4, Iss. 1
Open Access
Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells
Mohammadreza Gholamrezapour, Raziyeh Taghizadeh Ghavamabadi, Mohammad Mohsen Taghavi, et al.
Journal of Molecular Histology (2024) Vol. 56, Iss. 1
Closed Access


Diabetes Obesity Metabolic Syndrome (2023), Iss. 5
Open Access
Page 1

Scroll to top